Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation
Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation
Active, not recruiting · NCT05873205 · Registry updated 2026-04-02Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation | Hemic and Lymphatic Diseases, Neoplasms by Site, hematologic disorder, hematopoietic and lymphoid system neoplasm, neoplasm | Active, not recruiting | Phase 2 | 2026-04-02 | NCT05873205 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Memorial Sloan Kettering Cancer Center | 753 |
| Sanofi | 254 |
7 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) | Basking Ridge | United States | 131 |
| Memorial Sloan Kettering Bergen (Limited Protocol Activities) | Montvale | United States | 184 |
| Memorial Sloan Kettering Cancer Center (All Protocol Activities) | New York | United States | 230 |
| Memorial Sloan Kettering Monmouth (Limited Protocol Activities) | Middletown | United States | 186 |
| Memorial Sloan Kettering Nassau (All Protocol Activities) | Rockville Centre | United States | 27 |
| Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities ) | Commack | United States | 5 |
| Memorial Sloan Kettering Westchester (Limited Protocol Activities) | Harrison | United States | 166 |